CLAIMS

1. A compound of formula (I)

G_1-L-G_2

(I)

or a pharmaceutically acceptable salt thereof, wherein:

-G_1 is a radical selected from (IIa) y (IIb);



(IIa)



(IIb)

wherein -R' is an electron pair or a (C_1-C_3)-alkyl radical; with the condition that

(i) when -R' is an electron pair, a is a N=C double bond and the fused ring

is the biradical



thus radicals (IIa) and (IIb) are respectivelly (IIa') and (IIb'), and



(IIa')



(IIb')

(ii) when -R' is a (C_1-C_3)-alkyl radical, a is a N-C single bond and the fused ring is the triradical



thus radicals (IIa) and (IIb) are respectivelly (IIa") and (IIb");



(IIa")



(IIb")

wherein -R_1 to -R_{12} represent radicals, same or different, selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein -B- is a biradical selected from the group consisting of -CONH- , $-NR_{13}-$, -O- ,$-(CH_2)_nNH-$, $-(CH_2)_nO-$, $-CONH(CH_2)_uZ-$,

-$CONH(CH_2)_uCH(CH_2OH)CH_2Z$- , and -$CO[NHCHR''CO]_mO$- ; wherein -$R_{13}$ is selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy and (C_1-C_4)-alkylamino; -R'' are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3; m is an integer from 1 to 3; u is an integer from 1 to 3, and -Z- is a birradical of a oligonucleotide phosphate between 4 and 23 bases in length, linked to the methylene group at the 5' end or at the 3' end;

-L- is a single covalent bond or a covalent linking biradical selected from the following ones;

-$(CH_2)_rNR'''(CH_2)_s$-

-$(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t$-

wherein -R''' and -R'''' are radicals, same or different, selected from the group consisting of H and (C_1-C_3)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G_2 is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine;

with the proviso that (I) or its pharmaceutically acceptable salts is not one of the following compounds:
10H-quindoline-11-carboxamide;
2-bromo-10H-quindoline-11-carboxamide;
N-10H-quindolin-11-yl-1,3-propanediamine;
10H-quindolin-11-amine monohydrochloride;
10H-quindolin-11-methanol; or
N-[2-(dimethylamino)-ethyl]-10H-quindoline-4-carboxamide.

2. The compound according to claim 1, wherein (IIa) is the radical (IIa').



(IIa')

3. The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH- and $-NR_{13}-$.

4. The compound according to claim 2, wherein -B- is $-CO[NHCHR''CO]_mO-$.

5. The compound according to claim 4, wherein m = 2, the leftward -R'' is a glicine side chain, and the rightward -R'' is a arginine side chain.

6. The compound according to claim 2, wherein -B- is selected from the group consisting of $-CONH(CH_2)_uZ-$ and $-CONH(CH_2)_uCH(CH_2OH)CH_2Z-$.

7. The compound according to claim 6, wherein -Z- is selected from the group consisting of -TTCCGGAA- linked to the methylene group at the 3' or at the 5' end, and -CTTCTTCTTCT- linked at the 3' end.

8. The compound according to any of the claims 2-7 wherein -L- is a single covalent bond.

9. The compound according to any of the claims 2-7, wherein -L- is a covalent linking biradical selected from the following ones.

$-(CH_2)_rNR'''(CH_2)_s-$

$-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$

10. The compound according to claim 9, wherein -L- is the biradical $-(CH_2)_rNR'''(CH_2)_s-$, -R''' is methyl, and both r and s are 3.

11. The compound according to claim 9, wherein -L- is the covalent linking biradical -$(CH_2)_r NR'''(CH_2)_s NR''''(CH_2)_t$- , both -R''' and -R'''' are methyl; both r and t are 2, and s is 2 or 3.

12. The compound according to claim 1, wherein (IIa) is the radical (IIa").



(IIa")

13. The compound according to claim 12, wherein -B- is selected from the group consisiting of -CONH- and $-NR_{13}$- .

14. The compound according to claim 12, wherein -B- is
$-CO[NHCHR''CO]_m O$- .

15. The compound according to claim 14, wherein m = 2, the leftward -R" is a glicine side chain, and the rightward -R" is the arginine side chain.

16. The compound according to claim 12, wherein -B- is selected from the group consisiting of $-CONH(CH_2)_u Z$- and $-CONH(CH_2)_u CH(CH_2OH)CH_2 Z$- .

17. The compound according to claim 16, wherein -Z- is selected from the group consisting of -TTCCGGAA- linked to the methylene group at the 3' or at the 5' end, and
-CTTCTTCTTCT- linked at the 3' end.

18. The compound according to any of the claims 12-17, wherein -R' is methyl.

19. The compound according to claim 18, wherein -L- is a single covalent bond.

20. The compound according to claim 18, wherein -L- is a biradical selected from the following ones.

$-(CH_2)_r NR'''(CH_2)_s$-

$-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$

21. The compound according to claim 20, wherein -L- is the biradical $-(CH_2)_rNR'''(CH_2)_s-$, R''' is methyl, and both r and s are 3.

22. The compound according to claim 20, wherein -L- is the biradical $-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$, both -R''' and -R'''' are methyl; both r and t are 2, and s is an integer from 2 to 3.

23. The compound according to claim 1, which is selected from the group consisting of:

a) N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia);
b) N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ib);
c) N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolinyl]propyl]-methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic);
d) N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Id);
e) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);
f) N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);
g) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11-11'-carboxamide (Ig);
h) N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);
i) N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);
j) N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);
k) N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide);
l) 10H-indolo[3,2-b]quinoline-11-carbonyl-glicine-arginine;
m) N,N-dimethyl-*N'*-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-ethane-1,2-diamine (Ip);
n) N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);
o) N-1-[(5-hydroxymethyl-6-(5'-TTCCGGAA-3'-phosphate)-hexyl]- 10H-indolo[3,2-b]quinoline-11-carboxamide (Ir);

p) N-1-[(5-hydroxymethyl-6-(5'- CTTCCTCCTCT -3'-phosphate)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Is);
q) N-1-[6-(5'-phosphate-TTCCGGAA)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (It);
r) 10*H*-Indolo[3,2-*b*]quinoline-11-carboxylic acid (2-dimethylamino-ethyl)amide (Iu);
s) 10*H*-Indolo[3,2-*b*]quinoline-11-carboxylic acid (2-dimethylamino-propyl)amide (Iv);
t) *N,N*-dimethyl-*N'*-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-propane-1,2-diamine (Iw);
u) N-[3-[[3-[(10H-indolo[3,2-b]quinoline-4-carboxamide]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ix);
v) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);
w) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);
x) (3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);
y) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and
z) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

24. Use of the compound as defined in any of the claims 1 to 23, for the preparation of a medicament for the treatment of cancer.

25. A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in any of the claims 1 to 23, together with appropriate amounts of pharmaceutical excipients or carriers.